Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$24.05 - $34.20
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $13.73B |
EV | $23.75B |
Shares Outstanding | 433.32M |
Beta | 0.49 |
Analyst Rating | BUY |
Analyst Target Price | $39.45 |
P/E 2025E | 7.06x |
P/Revenue 2025E | 4.85x |
Revenue | -0.40% |
EPS | 12.40% |
Operating Cash Flow | 11.10% |
Free Cash Flow | 11.60% |
Revenue | 10.80% |
EPS | 11.50% |
Operating Cash Flow | 5.90% |
Free Cash Flow | 11.90% |
Gross Margin 2025E | 75.60% |
Net Profit Margin 2025E | 25.91% |
ROE 2025E | 29.26% |
ROCE 2024 | 12.75% |
DPS 2025E | $0.94 |
Payout Ratio 2025E | 20.94% |
Div. Yield 2025E | 2.95% |
DPS Last 3Y CAGR | 7.30% |
Price
%
1M
3M
6M
1Y
3Y
5Y
Royalty Pharma plc
RPRX
Sector
Healthcare
Industry
Biotechnology
CEO
Legorreta, Pablo
Employees
Website
www.royaltypharma.comIPO Date
2020-06-16
Headquarters
110 East 59th Street, New York, New York, 10022, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved